Tonix Pharmaceuticals Holding Corp.

TNXP · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions56.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$13.11M	$10.09M	$7.77M	–	–	–	–	–	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$6.64M	$7.76M	$4.74M	–	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$125.70M	-$136.70M	-$118.38M	-$112.09M	-$92.31M	-$50.51M	-$28.83M	-$21.29M	-$38.97M	-$48.16M
Operating income as a percentage of revenue.	-959.1%	-1354.3%	-1523.9%	–	–	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$124.02M	-$130.04M	-$116.66M	-$110.22M	-$92.29M	-$50.46M	-$28.62M	-$21.12M	-$38.84M	-$48.05M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-14.00	$-176.00	$-6.00	$-3.00	$-0.26	$-0.55	$-19.00	$-3.00	$-15.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-14.00	$-176.00	$-6.00	$-3.00	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$207.64M	$98.78M	$24.95M	$120.23M	$178.66M	$77.07M	$11.25M	$25.50M	$18.94M	$19.18M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$277.17M	$162.89M	$154.46M	$225.69M	$240.90M	–	$14.56M	$26.75M	$27.51M	$47.02M
All of the company's interest-bearing borrowings, short and long term combined.	–	$7.49M	$8.91M	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$32.02M	$23.33M	$48.93M	$18.51M	$22.18M	–	$5.14M	$2.14M	$2.15M	$6.76M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$245.15M	$139.56M	$105.53M	$207.18M	$218.72M	–	$9.42M	$24.62M	$25.36M	$40.26M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$99.84M	-$60.92M	-$102.00M	-$98.05M	-$75.56M	-$48.57M	-$26.68M	-$19.13M	-$37.31M	-$42.53M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$3.37M	$120000	$7.89M	$48.15M	$35.31M	$8.56M	$17000	$5000	$66000	$118000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$103.21M	-$61.05M	-$109.90M	-$146.20M	-$110.86M	-$57.13M	-$26.70M	-$19.13M	-$37.38M	-$42.65M

	You	Peer avg
Revenue Growth	+577.9%	-21.9%
ROE	-81.8%	-384.2%

Tonix Pharmaceuticals Holding Corp.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison